The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Slaney, Clare Y ^a,b   Möller, Andreas ^a,b   Hertzog, Paul J ^c   Parker, Belinda S ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Bone metastasis; Breast cancer; Interferon; Tumor immune surveillance

Indexed keywords

INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 7;

ADAPTIVE IMMUNITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL EXPANSION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG METASTASIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 84883291555     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22339     Document Type: Article

References (10)

1. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012; 11:479-97; PMID:22653217; http://dx.doi. org/10.1038/nrd2372.
2. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; In press; PMID:22908097; http://dx.doi. org/10.1158/1078-0432.CCR-12-1587.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science. 1203486.
4. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005; 3:1-13; PMID:15671244.
5. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772-7; PMID:15800576; http:// dx.doi.org/10.1038/nature03464.
6. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012; In press; PMID:22820642; http://dx.doi.org/10.1038/nm.2830.
7. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17:2619-27; PMID:21372217; http://dx.doi.org/10.1158/1078-0432.CCR-10-1114
8. Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumorbearing mice. Clin Cancer Res 2011; 17:1765-75; PMID:21233400; http://dx.doi.org/10.1158/1078-0432.CCR-10-2672.
9. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48; PMID:17063185; http:// dx.doi.org/10.1038/nri1961.
10. Repetto L, Giannessi PG, Campora E, Pronzato P, Vigani A, Naso C, et al. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Treat 1996; 39:235-8; PMID:8872332; http://dx.doi.org/10.1007/BF01806190.